Requirements of the PP2A regulatory subunits for rapamycin-induced GATA factor binding to the DAL5 promoter. Cells were grown in YNB-glutamine medium and treated with rapamycin (+Rap) (200 ng/ml) for 30 min. Control cells were similarly grown but untreated (Gln). ChIP was performed as described in the legend to Fig. . (A) Only the Pph21/22-Tpd3-Cdc55 complex is required to enable Gat1-Myc13 binding to PDAL5. Untagged wild-type (TB50), GAT1-MYC13 wild-type (FV063), GAT1-MYC13 pph21Δ pph22Δ (03879c), GAT1-MYC13 tpd3Δ (FV210), GAT1-MYC13 cdc55Δ (FV207), GAT1-MYC13 rts1Δ (FV208), and GAT1-MYC13 cdc55Δ rts1Δ (FV226) cells were subjected to ChIP analysis. (B) The Pph21/22-Tpd3-Cdc55 complex is required downstream of Ure2 to allow Gat1-Myc13 binding to PDAL5. Untagged wild-type (TB50), GAT1-MYC13 wild-type (FV063), GAT1-MYC13 ure2Δ (FV088), GAT1-MYC13 ure2Δ pph21Δ pph22Δ (FV103), GAT1-MYC13 ure2Δ tpd3Δ (FV278), GAT1-MYC13 ure2Δ cdc55Δ (FV224), and GAT1-MYC13 ure2Δ rts1Δ (FV272) cells were subjected to ChIP analysis. (C) The Pph21/22-Tpd3-Cdc55 complex is required downstream of Ure2 to allow Gln3-Myc13 binding to PDAL5. Untagged wild-type (TB50), GLN3-MYC13 wild-type (TB123), GLN3-MYC13 ure2Δ (TB138-1a), GLN3-MYC13 ure2Δ pph21Δ pph22Δ (FV165), GLN3-MYC13 ure2Δ tpd3Δ (FV277), GLN3-MYC13 ure2Δ cdc55Δ (FV274), and GLN3-MYC13 ure2Δ rts1Δ (FV273) cells were subjected to ChIP analysis.